Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

- Weber, Jeffrey S., Schadendorf, Dirk, Ascierto, Paolo A., Sandhu, Shahneen, Eigentler, Thomas, Gutzmer, Ralf, Hassel, Jessica C., Robert, Caroline, Carlino, Matteo S., Di Giacomo, Anna Maria, Butler, Marcus O., Muñoz-Couselo, Eva, Del Vecchio, Michele, Brown, Michael P., Rutkowski, P, Haydon, A, Grob, J-J, Schachter, J, Queirolo, P, de la Cruz-Merino, L, van der Westhuizen, Andre, Menzies, AM, Re, S, Larkin, James, Bas, T, de Pril, V, Braverman, J, Tenney, DJ, Tang, H, Long, GV, Atkinson, Victoria, Schenker, Michael, Pigozzo, Jacopo, Gogas, Helen, Dalle, Stéphane, Meyer, Nicolas

Association of pembrolizumab with tumor response and survival among patients with advanced melanoma

- Ribas, Antoni, Hamid, Omid, Gangadhar, Tara C., Hersey, Peter, Dronca, Roxana, Joseph, Richard W., Zarour, Hassane, Chmielowski, Bartosz, Lawrence, Donald P., Algazi, Alain, Rizvi, Naiyer A., Hoffner, Brianna, Daud, Adil, Mateus, Christine, Gergich, Kevin, Lindia, Jill A., Giannotti, Maxine, Li, Xiaoyun Nicole, Ebbinghaus, Scott, Kang, S. Peter, Robert, Caroline, Hodi, F. Stephen, Wolchok, Jedd D., Kefford, Richard, Joshua, Anthony M., Patnaik, Amita, Hwu, Wen-Jen, Weber, Jeffrey S.

Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab

- Hodi, F. Stephen, Hwu, Wen-Jen, Joshua, Anthony M., Hersey, Peter, Dronca, Roxana, Joseph, Richard, Hille, Darcy, Xue, Dahai, Li, Xiaoyun Nicole, Kang, S. Peter, Ebbinghaus, Scot, Perrone, Andrea, Kefford, Richard, Wolchok, Jedd D., Weber, Jeffrey S., Daud, Adil, Hamid, Omid, Patnaik, Amita, Ribas, Antoni, Robert, Caroline, Gangadhar, Tara C.

Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma

- Daud, Adil I, Wolchok, Jedd D., Joseph, Richard, Gangadhar, Tara C., Dronca, Roxana, Patnaik, Amita, Zarour, Hassane, Roach, Charlotte, Toland, Grant, Lunceford, Jared K., Li, Xiaoyun Nicole, Emancipator, Kenneth, Robert, Caroline, Dolled-Filhart, Marisa, Kang, S. Peter, Ebbinghaus, Scot, Hamid, Omid, Hwu, Wen-Jen, Weber, Jeffrey S., Ribas, Antoni, Hodi, F. Stephen, Joshua, Anthony M., Kefford, Richard, Hersey, Peter

Side effects and toxicities of targeted therapies in stage IV melanoma

- Ascierto, Paolo A., Bastholt, Lars, Hersey, Peter, Cinat, Gabriela, Eggermont, Alexander M. M., Hauschild, Axel, Espinosa, Enrique, Robert, Caroline

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma

- Hamid, Omid, Robert, Caroline, Dronca, Roxana, Gangadhar, Tara C., Patnaik, Amita, Zarour, Hassane, Joshua, Anthony M., Gergich, Kevin, Elassaiss-Schaap, Jeroen, Algazi, Alain, Mateus, Christine, Boasberg, Peter, Daud, Adil, Tumeh, Paul C., Chmielowski, Bartosz, Ebbinghaus, Scot W., Li, Xiaoyun Nicole, Kang, S. Peter, Ribas, Antoni, Hodi, F. Stephen, Hwu, Wen-Jen, Kefford, Richard, Wolchok, Jedd D., Hersey, Peter, Joseph, Richard W., Weber, Jeffrey S.

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

- Kirkwood, John M., Lorigan, Paul, Hersey, Peter, Hauschild, Axel, Robert, Caroline, McDermott, David, Marshall, Margaret A., Gomez-Navarro, Jesus, Liang, Jane Q., Bulanhagui, Cecile A.

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with Carboplatin and Paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

- Hauschild, Axel, Agarwala, Sanjiv S, Peschel, Christian, Schadendorf, Dirk, Garbe, Claus, O'Day, Steven, Daud, Adil, White, J. Michael, Xia, Chenghua, Patel, Kiran, Kirkwood, John M., Keilholz, Ulrich, Trefzer, Uwe, Hogg, David, Robert, Caroline, Hersey, Peter, Eggermont, Alexander, Grabbe, Stephan, Gonzalez, Rene, Gille, Jens